Efficacy of penicillin vs. amoxicillin in children with group A beta hemolytic streptococcal tonsillopharyngitis
Correne Curtin-Wirt1, Janet R Casey, Patrick C Murray
1Elmwood Pediatric Group, University of Rochester Medical Center, 601 Elmwood Avenue, Rochester, NY 14642, USA.
Insights
Amoxicillin may be more effective than penicillin for treating group A beta-hemolytic streptococcal tonsillopharyngitis. This study found amoxicillin led to higher bacteriologic and clinical cure rates in children.
Area of Science:
- Infectious Diseases
- Pediatrics
- Pharmacology
Background:
- Group A beta-hemolytic streptococcal (GABHS) tonsillopharyngitis is a common childhood illness.
- Penicillin has been the standard treatment, but alternative therapies are continually evaluated for improved efficacy.
Purpose of the Study:
- To compare the bacteriologic and clinical effectiveness of oral penicillin versus amoxicillin as primary treatment for GABHS tonsillopharyngitis in children.
Main Methods:
- A prospective observational study over 18 months involving children with laboratory-confirmed GABHS tonsillopharyngitis.
- Patients received either oral penicillin V or amoxicillin.
- Outcomes assessed included bacteriologic and clinical cure rates at follow-up examination.
Main Results:
- Amoxicillin achieved a higher bacteriologic cure rate (76%) compared to penicillin (64%, p=0.04).
- Clinical cure rates were also significantly higher for amoxicillin (84%) versus penicillin (73%, p=0.03).
- Adjusted analyses (logistic regression) confirmed amoxicillin's superiority (OR=1.84 for bacteriologic, OR=1.99 for clinical cure).
Conclusions:
- Amoxicillin demonstrates potential superiority over penicillin V for both bacteriologic and clinical outcomes in treating GABHS tonsillopharyngitis.
- These findings suggest amoxicillin may be a preferred first-line agent for this common pediatric infection.
Abstract:
The purpose of this study was to compare the bacteriologic and clinical efficacy of oral penicillin versus amoxicillin as first-line therapy for group A beta-hemolytic streptococcal (GABHS) tonsillopharyngitis. The prospective observational study was conducted over 18 months (January 2000-June 2001). Children enrolled had acute onset of symptoms and signs and a laboratory-documented GABHS tonsillopharyngitis illness. Follow-up examination and laboratory testing occurred 10 +/- 4 days following completion of treatment. In total, 389 patients were enrolled (intent-to-treat group): 195 received penicillin V and 194 received amoxicillin. Fifty-six of the penicillin-treated and 57 amoxicillin-treated patients refused to take the drug, or were noncompliant, or did not return for the follow-up visit, leaving 276 patients in the per-protocol group: 139 penicillin-treated and 137 amoxicillin-treated. Bacteriologic cure for amoxicillin-treated children occurred in 76% versus 64% in the penicillin-treated children (p = 0.04). The clinical cure rate for amoxicillin-treated children was 84% compared to 73% in the penicillin-treated children (p = 0.03). Since treatment allocation was not randomized, logistic regression analysis was used to adjust for treatment group differences. The odds ratio (OR) estimate for cure for patients in the amoxicillin versus penicillin V treatment group remained significant (OR = 1.84, 95% confidence interval 1.02-3.29); the same was true for dinical cure (OR = 1.99, 95% CI = 1.02-3.87). Amoxicillin may be superior to penicillin for bacteriologic and clinical cure of GABHS tonsillopharyngitis.
Related Concept Videos
Production of Antibiotics
Streptococcal Pharyngitis
Antimicrobial Effectiveness
Chronic Pharyngitis
Etiology
It often arises from persistent viral or bacterial infections affecting sinuses and tonsils.
Additional contributing factors include inadequate dental hygiene, mouth breathing, recurring tonsillitis, allergic rhinitis, laryngopharyngeal reflux, and exposure to smoke, chemicals, and other environmental pollutants. Allergic reactions to pollen, mold, and pet dander, chronic cough, excessive voice usage,...
Tonsillitis II: Management
Mechanism of Antibiotic Resistance in MRSA

